Phase II Clinical Trial With the Combination Gemcitabine, Oxaliplatin and Vinorelbine as First Line Treatment in Patients With Non-small Cell Bronchopulmonary Cancer (GON)

NCT00271271 Phase 2 COMPLETED

Primary: ·To evaluate the activity of the combination of gemcitabine, oxaliplatin and vinorelbine as first line treatment in patients with non-small cell bronchopulmonary cancer Secondary: ·To evaluate the toxicity of the combination

Details

Lead sponsor	Sanofi
Phase	Phase 2
Status	COMPLETED
Enrolment	40
Start date	2003-06
Completion	2006-10

Conditions

• Non Small Cell Lung Cancer

Interventions

• oxaliplatine / gemcitabine / Vinorelbine

Primary outcomes

• Objective rate of response (ORR) according to the RECIST criterion, as evaluated by a review panel of outside experts.

Countries

France